{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:36:12Z","timestamp":1790444172361,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Giant Food Children's Cancer Research Fund"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health\/National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA015396"],"award-info":[{"award-number":["P01 CA015396"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health\/National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.bbmt.2016.11.016","type":"journal-article","created":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T19:57:38Z","timestamp":1479844658000},"page":"325-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4193-5526","authenticated-orcid":false,"given":"Orly R.","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-7131","authenticated-orcid":false,"given":"Jessica","family":"Buddenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen R.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Gamper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Zambidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas J.","family":"Llosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Robey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0927-3681","authenticated-orcid":false,"given":"Mary Jo","family":"Holuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette L.","family":"Kasamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon R.","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Luznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Symons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.11.016_bib0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"NEJM"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0015","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0020","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0025","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","article-title":"Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults","volume":"33","author":"Kasamon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0030","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.bbmt.2015.07.012","article-title":"Phase II study of nonmyeloablative allogeneic bone marrow transplantation for b cell lymphoma with post-transplantation rituximab and donor selection based first on non-HLA factors","volume":"21","author":"Kanakry","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bbmt.2015.10.015","article-title":"Outcomes of haploidentical stem cell transplantation for lymphoma with melphalan-based conditioning","volume":"22","author":"Brammer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0040","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7802967","article-title":"HLA haplotype mismatch transplants and posttransplant cyclophosphamide","volume":"2016","author":"Bacigalupo","year":"2016","journal-title":"Adv Hematol"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbmt.2015.09.002","volume":"22","author":"Bashey","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0050","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9736564","article-title":"Myeloablative conditioning with PBSC grafts for T cell-replete haploidentical donor transplantation using posttransplant cyclophosphamide","volume":"2016","author":"Solomon","year":"2016","journal-title":"Adv Hematol"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0060","doi-asserted-by":"crossref","first-page":"e86252","DOI":"10.1172\/jci.insight.86252","article-title":"Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide","volume":"1","author":"Kanakry","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0065","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T Cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0070","doi-asserted-by":"crossref","first-page":"e974393","DOI":"10.4161\/2162402X.2014.974393","article-title":"Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent","volume":"4","author":"Kanakry","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12026-009-8139-0","article-title":"High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation","volume":"47","author":"Luznik","year":"2010","journal-title":"Immunol Res"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0080","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","article-title":"Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome","volume":"16","author":"Kasamon","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0085","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0090","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0095","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/blood-2013-10-535716","article-title":"Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens","volume":"123","author":"Bitan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0100","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood-2009-01-196303","article-title":"Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313","volume":"114","author":"Pulsipher","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0105","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2012.12.005","article-title":"Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic\u00a0hematopoietic stem cell transplantation in\u00a0100\u00a0consecutive pediatric recipients","volume":"19","author":"Satwani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0110","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.bbmt.2010.03.009","article-title":"Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia","volume":"16","author":"Verneris","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/bmt.2008.353","article-title":"Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen","volume":"43","author":"Bolanos-Meade","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0120","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0125","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0130","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0135","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1309\/LRKX8CE7GVPCR1FT","article-title":"Hepatosplenic and other \u03b3\u0394 T-cell lymphomas","volume":"127","author":"Vega","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0140","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0145","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1995.13.5.1103","article-title":"Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation","volume":"13","author":"Bedi","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0150","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0090-4295(82)90633-1","article-title":"Prevention of cyclophosphamide-induced hemorrhagic cystitis","volume":"20","author":"Droller","year":"1982","journal-title":"Urology"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0155","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3109\/08880018.2014.961214","article-title":"Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies","volume":"31","author":"Sawada","year":"2014","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0160","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/bmt.2016.161","volume":"51","author":"Dufort","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib9000","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0165","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0170","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1038\/leu.2012.123","article-title":"Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis","volume":"26","author":"Ruggeri","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0175","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.beha.2013.10.008","article-title":"Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia","volume":"26","author":"Appelbaum","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0180","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/cncr.29871","article-title":"Biologic and clinical characteristics of adolescent and young adult cancers: acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma","volume":"122","author":"Tricoli","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0185","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1182\/blood-2014-11-551481","article-title":"How I treat acute lymphoblastic leukemia in older adolescents and young adults","volume":"125","author":"Curran","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0190","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2015.92","article-title":"Adolescent and young adult patients with cancer: a milieu of unique features","volume":"12","author":"Sender","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0195","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/bmt.2015.7","article-title":"Reduced-intensity conditioned allogeneic SCT in adults with AML","volume":"50","author":"Reshef","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0200","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.seminoncol.2009.03.003","article-title":"Cancer in young adults 20 to 39 years of age: overview","volume":"36","author":"Bleyer","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0205","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/bmt.2014.197","article-title":"Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas","volume":"49","author":"Castagna","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0210","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0215","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0220","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3324\/haematol.2012.069393","article-title":"Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center","volume":"98","author":"Gibb","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0225","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood-2010-01-261958","article-title":"Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors","volume":"116","author":"Shaw","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0230","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.11.016_bib0235","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbmt.2013.11.020","article-title":"HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation","volume":"20","author":"Zeidan","year":"2014","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911630516X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911630516X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:57:18Z","timestamp":1761058638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911630516X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S108387911630516X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.11.016","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}